Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2008-09-09
2008-09-09
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S161000, C514S357000, C546S337000
Reexamination Certificate
active
10507864
ABSTRACT:
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
REFERENCES:
patent: 3222395 (1965-12-01), Schultz et al.
patent: 4150052 (1979-04-01), Watson et al.
patent: 4973587 (1990-11-01), Ward et al.
patent: 5013837 (1991-05-01), Ward et al.
patent: 5081122 (1992-01-01), Ward
patent: 5112820 (1992-05-01), Ward
patent: 5292736 (1994-03-01), Kumar et al.
patent: 5462931 (1995-10-01), Shaber et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6972295 (2005-12-01), Hagmann et al.
patent: 2003/0105132 (2003-06-01), Challenger et al.
patent: 2004/0058820 (2004-03-01), Hagmann et al.
patent: 2005/0154202 (2005-07-01), Hagmann et al.
patent: 2005/0234061 (2005-10-01), Hagmann et al.
patent: 2006/0106071 (2006-05-01), Lin et al.
patent: 0656354 (1995-06-01), None
patent: 658546 (2001-05-01), None
patent: 1328269 (2004-05-01), None
patent: 11-080124 (1999-03-01), None
patent: WO 96/33159 (1996-10-01), None
patent: WO 97/29079 (1997-08-01), None
patent: WO 98/31227 (1998-07-01), None
patent: WO 98/33765 (1998-08-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 98/41519 (1998-09-01), None
patent: WO 99/02499 (1999-01-01), None
patent: WO 99/11608 (1999-03-01), None
patent: WO 99/31048 (1999-06-01), None
patent: WO 00/10967 (2000-03-01), None
patent: WO 00/10968 (2000-03-01), None
patent: WO 01/09120 (2001-02-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 01/85092 (2001-11-01), None
patent: WO 02/076945 (2002-10-01), None
patent: WO 02/100344 (2002-12-01), None
patent: WO 03/077847 (2003-09-01), None
patent: WO 03/082256 (2003-10-01), None
patent: WO 03/086288 (2003-10-01), None
patent: WO 03/087037 (2003-10-01), None
“Spiro compounds” IUPAC Compendium of Chemical Terminology 2nd Edition (1997) Electronic version, http://goldbook.iupac.org/S05881.html.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface. 40-43, 72-79, 143-149, 182-197.
P. H. Reggio “Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors” Prostaglandins, Leukotrienes and Essential Fatty Acids 2002, 66, 143-160.
Lea W. Padgett “Recent developments in cannabinoid ligands” Life Sciences 2005, 77, 1767-1798.
Martin, Yvonne C. et. al. “Do Structurally Similar Molecules Have Similar Biological Activity?” Journal of Medicinal Chemistry 2002, 45, 4350-4358.
Hiroyuki Kai “2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: Discovery of CB2 receptor selective compounds” Bioorganic & Medicinal Chemistry Letters 2007, 17, 4030-4034.
Jones, Maitland Organic Chemistry Norton: New York, 1997, p. 84-99.
U.S. Appl. No. 60/515,705, Shah et al.
Gallop et al., Database on Caplus on Stn No. 138:24957 (WO 02/100344).
Barth, Exp. Opin. Ther. Patents, vol. 8 (1998), pp. 301-313, “Cannabinoid receptor agonists and antagonists”.
Xiang et al., Ann. Rep. Med. Chem., A. Doherty, ed., Academic Press, NY (1999), vol. 34, pp. 199-208, “Chap. 20. Pharrmacology of cannabinoid receptor agonists and antagonists”.
Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, “Recent advances in cannabinoid receptor agonists and antagonists”.
Piomelli et al., Trends in Pharm. Sci., vol. 21 (2000), pp. 218-224, “The endocannabinoid system as a target for therapeutic drugs”.
Lack et al., J. Pharmacol. Expt'l. Therap., vol. 139 (1963), pp. 248-258, “The intestimal action of benzmalecene: The Relationship of its hypocholesterolemic effect to active transport of bile salts and other substances”.
Davey et al., J. Pharm. Pharmacol., vol. 15 (1963), pp. 178-182, “The mode of actio nof tyramine”.
Berglund et al., Database Caplus on Stn No. 133:53157, Drug Design & Discovery, vol. 16 (2000), pp. 281-294, “Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 . . . ”.
Berglund et al., Drug Design & Discovery, vol. 16 (2000), pp. 281-294, “Developent of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation”.
Nicolaus, Decision Making in Drug Res. (1983), pp. 173-186, XP-002197412, “Symbiotic approach to drug design”.
Goulet Mark T.
Hagmann William K.
Jewell James P.
Lin Linus S.
Shah Shrenik K.
Brown Baerbel R.
Desai Rita
Fitch Catherine D.
Merck & Co. , Inc.
O'Dell David K
LandOfFree
Diphenyl cyclopentyl amides as cannabinoid-1 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diphenyl cyclopentyl amides as cannabinoid-1 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphenyl cyclopentyl amides as cannabinoid-1 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3916559